☰

Karisa Colleen Schreck - Publications

Affiliations: 
2012 Johns Hopkins University, Baltimore, MD 
Tree Info Grants Similar researchers PubMed Report error

20/53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Schreck KC, Patel MP, Wemmer J, Grossman SA, Peters KB. RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. Neuro-Oncology Practice. 7: 369-375. PMID 32765888 DOI: 10.1093/Nop/Npaa006  0.33
2020 Naidoo J, Schreck KC, Hu C, Douville CB, Santa-Maria CA, Connolly RM, Holdhoff M, Lipson EJ, Parkinson R, Riemer J, Barnes A, Venkatesan A, Bettegowda C, Grossman SA, Brahmer JR. Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response. Journal of Clinical Oncology. 38: e14506-e14506. DOI: 10.1200/Jco.2020.38.15_Suppl.E14506  0.339
2019 Schreck KC, Grossman SA, Pratilas CA. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers. 11. PMID 31466300 DOI: 10.3390/Cancers11091262  0.417
2019 Ananth YV, Schreck K. CGE19-063: Creating a Clinical-Molecular Database to Study Patients with BRAF V600E-Mutated Brain Tumors Journal of the National Comprehensive Cancer Network. 17: CGE19-063. DOI: 10.6004/Jnccn.2018.7137  0.417
2019 Schreck KC, Allen A, Wang J, Pratilas CA. Abstract B074: Sapanisertib in combination with trametinib in glioblastoma models enhances target inhibition and antitumor activity Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B074  0.396
2018 Schreck KC, Grossman SA. Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System. Oncology (Williston Park, N.Y.). 32: 555-60, 569. PMID 30474103  0.328
2018 Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA. Concurrent BRAF/MEK Inhibitors in V600-Mutant High-Grade Primary Brain Tumors. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 343-347. PMID 29632053 DOI: 10.6004/Jnccn.2017.7052  0.445
2015 Brandt WD, Schreck KC, Bar EE, Taylor I, Marchionni L, Raabe E, Eberhart CG, Rodriguez FJ. Notch signaling activation in pediatric low-grade astrocytoma. Journal of Neuropathology and Experimental Neurology. 74: 121-31. PMID 25575134 DOI: 10.1097/Nen.0000000000000155  0.516
2015 Brandt WD, Schreck KC, Bar EE, Taylor I, Marchionni L, Raabe E, Eberhart CG, Rodriguez FJ. Lg-04Notch Signaling Activation In Pediatric Low-Grade Astrocytoma. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov061.73  0.52
2013 Heaphy CM, Schreck KC, Raabe E, Mao XG, An P, Chu Q, Poh W, Jiao Y, Rodriguez FJ, Odia Y, Meeker AK, Eberhart CG. A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathologica. 126: 607-8. PMID 24022427 DOI: 10.1007/S00401-013-1174-X  0.37
2012 Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW, Eberhart CG. Notch signaling promotes growth and invasion in uveal melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 654-65. PMID 22228632 DOI: 10.1158/1078-0432.Ccr-11-1406  0.459
2011 Pierfelice TJ, Schreck KC, Dang L, Asnaghi L, Gaiano N, Eberhart CG. Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Research. 71: 1115-25. PMID 21245095 DOI: 10.1158/0008-5472.Can-10-0690  0.649
2011 Asnaghi L, Coonfield ML, Schreck KC, Bar EE, Handa J, Merbs S, Ebrahimi KB, Harbour JW, Eberhart CG. Abstract 1415: The Notch ligand Jag 2 promotes growth and invasion in uveal melanoma cells Cancer Research. 71: 1415-1415. DOI: 10.1158/1538-7445.Am2011-1415  0.399
2010 Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6060-70. PMID 21169257 DOI: 10.1158/1078-0432.Ccr-10-1624  0.733
2010 Silver DL, Watkins-Chow DE, Schreck KC, Pierfelice TJ, Larson DM, Burnetti AJ, Liaw HJ, Myung K, Walsh CA, Gaiano N, Pavan WJ. The exon junction complex component Magoh controls brain size by regulating neural stem cell division. Nature Neuroscience. 13: 551-8. PMID 20364144 DOI: 10.1038/Nn.2527  0.667
2010 Asnaghi L, Coonfield ML, Schreck KC, Bar EE, Handa J, Merbs S, Ebrahimi K, Harbour JW, Eberhart CG. Abstract 4141: Notch signaling: A new potential target in the treatment of uveal melanoma Cancer Research. 70: 4141-4141. DOI: 10.1158/1538-7445.Am10-4141  0.422
2010 Schreck KC, Taylor P, Bar EE, Gopalakrishnan V, Gaiano N, Eberhart CG. Abstract 14: Targeting Notch in malignant brain tumors: Crosstalk with Hedgehog as a potential mechanism of treatment resistance Cancer Research. 70: 14-14. DOI: 10.1158/1538-7445.Am10-14  0.748
2009 Schreck KC, Gaiano N. PML: a tumor suppressor essential for neocortical development. Nature Neuroscience. 12: 108-10. PMID 19172164 DOI: 10.1038/Nn0209-108  0.738
2008 Pierfelice TJ, Schreck KC, Eberhart CG, Gaiano N. Notch, neural stem cells, and brain tumors. Cold Spring Harbor Symposia On Quantitative Biology. 73: 367-75. PMID 19022772 DOI: 10.1101/Sqb.2008.73.013  0.695
2007 Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, Eberhart CG. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (Dayton, Ohio). 25: 2524-33. PMID 17628016 DOI: 10.1634/Stemcells.2007-0166  0.571
Low-probability matches (unlikely to be authored by this person)
2014 Blakeley J, Schreck KC, Evans DG, Korf BR, Zagzag D, Karajannis MA, Bergner AL, Belzberg AJ. Clinical response to bevacizumab in schwannomatosis. Neurology. 83: 1986-7. PMID 25339217 DOI: 10.1212/Wnl.0000000000000997  0.3
2019 Berrington A, Schreck KC, Barron BJ, Blair L, Lin DDM, Hartman AL, Kossoff E, Easter L, Whitlow CT, Jung Y, Hsu FC, Cervenka MC, Blakeley JO, Barker PB, Strowd RE. Cerebral Ketones Detected by 3T MR Spectroscopy in Patients with High-Grade Glioma on an Atkins-Based Diet. Ajnr. American Journal of Neuroradiology. PMID 31649157 DOI: 10.3174/Ajnr.A6287  0.295
2019 Schreck K, Hsu F, Berrington A, Henry-Barron BJ, Blair L, Hartman A, Kossoff E, Easter L, Self M, Whitlow C, Barker P, Cervenka M, O Blakeley J, Strowd R. ACTR-44. FEASIBILITY, PHARMACODYNAMICS, AND BIOLOGIC ACTIVITY OF THE GLIOMA ATKINS-BASED DIET (GLAD) FOR PREVENTING TUMOR RECURRENCE IN GLIOMA PATIENTS Neuro-Oncology. 21: vi23-vi23. DOI: 10.1093/Neuonc/Noz175.086  0.264
2020 Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, ... Schreck KC, et al. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology. PMID 31974566 DOI: 10.1093/Neuonc/Noaa015  0.253
2017 Schreck KC, Berrington A, Barron BM, Blair L, Hartman A, Kossoff E, Easter L, Whitlow C, Hsu F, Cervenka MC, Blakeley JO, Barker PB, Strowd RE. NIMG-94. FEASIBILITY OF PROTON MRS FOR ASSESSING CEREBRAL METABOLIC ACTIVITY OF AN ATKINS-BASED DIET IN PATIENTS WITH GLIOMA Neuro-Oncology. 19: vi163-vi163. DOI: 10.1093/Neuonc/Nox168.663  0.247
2018 Schreck K, Ranjan S, Skorupan N, Ames H, Holdhoff M. PATH-35. FREQUENCY AND CHARACTERISTICS OF H3K27M-MUTATION IN ADULTS WITH RADIOGRAPHICALLY-DETERMINED MIDLINE GLIOMAS Neuro-Oncology. 20: vi166-vi166. DOI: 10.1093/Neuonc/Noy148.691  0.241
2019 Zammar S, Madden D, Schreck K, Berens M, Dietrich J, Glantz M. EXTH-39. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY Neuro-Oncology. 21: vi90-vi90. DOI: 10.1093/Neuonc/Noz175.371  0.239
2019 Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. Journal of Neuro-Oncology. PMID 30864101 DOI: 10.1007/S11060-019-03134-X  0.237
2018 Schreck K, Vera E, Aboud O, Acquaye A, Boris L, Briceno N, Brown M, Chung H, Crandon S, Garren N, Ji M, Levine J, Patel S, Quezado M, Raffeld M, et al. PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS Neuro-Oncology. 20: vi164-vi164. DOI: 10.1093/Neuonc/Noy148.684  0.234
2015 Schreck KC, Schneider L, Geocadin RG. Clinical Reasoning: A 44-year-old woman with rapidly progressive weakness and ophthalmoplegia. Neurology. 85: e22-7. PMID 26195241 DOI: 10.1212/Wnl.0000000000001761  0.224
2017 Schreck KC, Lwin M, Strowd RE, Henry-Barron BJ, Blakeley JO, Cervenka MC. Effect of ketogenic diets on leukocyte counts in patients with epilepsy. Nutritional Neuroscience. 1-6. PMID 29254457 DOI: 10.1080/1028415X.2017.1416740  0.22
2020 Schreck KC, Allen AN, Wang J, Pratilas CA. Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma. Neuro-Oncology Advances. 2: vdaa138. PMID 33235998 DOI: 10.1093/noajnl/vdaa138  0.21
2022 Ye X, Schreck KC, Ozer BH, Grossman SA. High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes. Expert Review of Anticancer Therapy. 1-13. PMID 35130447 DOI: 10.1080/14737140.2022.2038138  0.21
2017 Grossman SA, Schreck KC, Ballman K, Alexander B. Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. Neuro-Oncology. 19: 469-474. PMID 28388713 DOI: 10.1093/Neuonc/Nox030  0.207
2022 Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene. PMID 35459782 DOI: 10.1038/s41388-022-02305-x  0.205
2016 Schreck KC, Orthmann-Murphy JL, Newsome SD. Clinical Reasoning: A 70-year-old woman with acute-onset weakness and progressive hemiataxia. Neurology. 87: e264-e268. PMID 27895250 DOI: 10.1212/Wnl.0000000000003377  0.196
2024 Schreck KC, Strowd RE, Nabors LB, Ellingson BM, Chang M, Tan SK, Abdullaev Z, Turakulov R, Aldape K, Danda N, Desideri S, Fisher J, Iacoboni M, Surakus T, Rudek MA, et al. Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38446982 DOI: 10.1158/1078-0432.CCR-23-3241  0.195
2017 Raza N, Schreck KC. Neurosarcoidosis Presenting With Recurrent Strokes: A Case Report and Literature Review. The Neurohospitalist. 7: 91-95. PMID 28400903 DOI: 10.1177/1941874416656730  0.193
2023 Schreck KC, Langat P, Bhave VM, Li T, Woodward E, Pratilas CA, Eberhart CG, Bi WL. Integrated molecular and clinical analysis of BRAF-mutant glioma in adults. Npj Precision Oncology. 7: 23. PMID 36854806 DOI: 10.1038/s41698-023-00359-y  0.19
2023 Parker M, Kalluri A, Materi J, Gujar SK, Schreck K, Mukherjee D, Weingart J, Brem H, Redmond KJ, Lucas CG, Bettegowda C, Rincon-Torroella J. Management and Molecular Characterization of Intraventricular Glioblastoma: A Single-Institution Case Series. International Journal of Molecular Sciences. 24. PMID 37686092 DOI: 10.3390/ijms241713285  0.189
2022 Munjapara V, Heumann T, Schreck KC, Gross JM, Perez-Heydrich C, Gujar SK, Eberhart CG, Holdhoff M. BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report. Case Reports in Oncology. 15: 909-917. PMID 36825105 DOI: 10.1159/000525660  0.179
2023 Douville C, Curtis S, Summers M, Azad TD, Rincon-Torroella J, Wang Y, Mattox A, Avigdor B, Dudley J, Materi J, Raj D, Nair S, Bhanja D, Tuohy K, Dobbyn L, ... ... Schreck KC, et al. Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid. Cell Reports. Medicine. 4: 101148. PMID 37552989 DOI: 10.1016/j.xcrm.2023.101148  0.17
2023 Huang Q, Wu J, Le N, Shen Y, Guo P, Schreck KC, Kamson D, Blair L, Heo HY, Li X, Li W, Sair HL, Blakeley JO, Laterra J, Holdhoff M, et al. CEST2022: Amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatment high-grade gliomas. Magnetic Resonance Imaging. PMID 37321378 DOI: 10.1016/j.mri.2023.06.003  0.163
2021 Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, Green AL, Jones C, Jones KL, Kilburn LB, Nazemi KJ, Samuel D, Sanford B, Solomon DA, Wang J, et al. Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAF V600E mutant human glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34433654 DOI: 10.1158/1078-0432.CCR-21-2660  0.16
2021 Naidoo J, Schreck KC, Fu W, Hu C, Carvajal-Gonzalez A, Connolly RM, Santa-Maria CA, Lipson EJ, Holdhoff M, Forde PM, Douville C, Riemer J, Barnes A, Redmond KJ, Kleinberg L, et al. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. Journal For Immunotherapy of Cancer. 9. PMID 34380662 DOI: 10.1136/jitc-2021-002473  0.152
2021 Natsumeda M, Chang M, Gabdulkhaev R, Takahashi H, Tsukamoto Y, Kanemaru Y, Okada M, Oishi M, Okamoto K, Rodriguez FJ, Kakita A, Fujii Y, Schreck KC. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathology. PMID 34216310 DOI: 10.1007/s10014-021-00407-0  0.136
2021 Natsumeda M, Chang M, Gabdulkhaev R, Takahashi H, Tsukamoto Y, Kanemaru Y, Okada M, Oishi M, Okamoto K, Rodriguez FJ, Kakita A, Fujii Y, Schreck KC. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathology. PMID 34216310 DOI: 10.1007/s10014-021-00407-0  0.136
2021 Coltin H, Sundaresan L, Smith KS, Skowron P, Massimi L, Eberhart CG, Schreck KC, Gupta N, Weiss WA, Tirapelli D, Carlotti C, Li KKW, Ryzhova M, Golanov A, Zheludkova O, et al. Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica. PMID 34409497 DOI: 10.1007/s00401-021-02358-4  0.116
2021 Schreck KC, Hsu FC, Berrington A, Henry-Barron B, Vizthum D, Blair L, Kossoff EH, Easter L, Whitlow CT, Barker PB, Cervenka MC, Blakeley JO, Strowd RE. Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma. Neurology. PMID 34233941 DOI: 10.1212/WNL.0000000000012386  0.113
2023 Ghanem P, Fatteh M, Kamson DO, Balan A, Chang M, Tao J, Blakeley J, Canzoniero J, Grossman SA, Marrone K, Schreck KC, Anagnostou V. Druggable genomic landscapes of high-grade gliomas. Frontiers in Medicine. 10: 1254955. PMID 38143440 DOI: 10.3389/fmed.2023.1254955  0.103
2022 Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA. Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene. PMID 35534540 DOI: 10.1038/s41388-022-02342-6  0.095
2015 Schreck KC, Schneider L, Geocadin RG. Clinical Reasoning: A 44-year-old woman with rapidly progressive weakness and ophthalmoplegia Neurology. 85: e22-e27. DOI: 10.1212/WNL.0000000000001761  0.049
2023 Zhang KY, Ramlal B, Schreck KC, Eberhart CG, Lucas CG. Frontal lobe mass in a 46-year-old woman. Brain Pathology (Zurich, Switzerland). e13211. PMID 37712207 DOI: 10.1111/bpa.13211  0.015
Hide low-probability matches.